Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

TRENDING
More Virtual Banks to Switch On in Hong Kong
Geely’s Volvo Links Up With China Unicom on 5G for Self-Driving Cars
Property Giant Evergrande Pays 12% in New Bond Financing
LATEST
ByteDance Readying Assault on Tencent’s Mobile Gaming Kingdom
Hu Shuli: Reflections on Myanmar’s Leader
Property Giant Evergrande Pays 12% in New Bond Financing
More Virtual Banks to Switch On in Hong Kong
Geely’s Volvo Links Up With China Unicom on 5G for Self-Driving Cars
Investors Cash Out of Online Lender Qudian’s After Guidance Withdrawal
China-U.S. Trade Deal Hardly Addresses Issue of Technology Transfer
Tesla Eyes Design and Research Center for ‘Chinese-Style’ Cars
IPhone Manufacturer Gets Into Electric Cars Via Fiat Venture
Exclusive: Another PBOC Official Is Under Probe, Possibly Tied to Third-Party Payment
‘Chunyun’ Helps Travel-Related Apps Grow Their Active Users in December, Survey Shows
Rising Air Pollution Across China Clouds Clear Skies in Beijing and Shanghai: Report
Huawei Asks U.K. Developers to Help Build App Ecosystem Amid Android Ban
WeChat Tests Pay-to-Read Feature for Public Blogging Accounts
Listed Internet Firms Rally in Fourth Quarter
Beijing Media Company Enlight Announce One Billion Yuan Investment in Animation
JD.com Doubles Down on Smaller-Cities Expansion to Bolster 2020 Growth
Big China Tech Feasts, as Startups Go Hungry
Beyond Meat Shares Rise on Executive’s China Comments
Government Push on Electronic Toll Collection System Fuels Supplier Growth
Chinese DNA Sequencing Firm BGI Faces Legal Battle with Illumina

By Wang Luyao and Han Wei / May 24, 2019 02:59 AM / Business & Tech

Photo: VCG

Photo: VCG

Chinese genomics giant BGI Group said it is prepared in the face of rising legal disputes in Europe and may resort to counterclaims to fight patent infringement allegations.

BGI is “actively responding to recent patent disputes and will take corresponding legal actions,” BGI said in a statement to Caixin Thursday, adding that it “will not rule out the use of legal weapons such as counterclaims to protect its legal rights.”

BGI’s subsidiary BGI Europe was sued by Illumina Inc. in Denmark on alleged patent infringement last week. The complaint alleged BGI's sequencing products and related sequencing chemistry reagents infringe on Illumina's European patent.

The case followed another infringement suit filed by Illumina in Germany against another BGI subsidiary, Latvia MGI Tech, in March.

In the statement, BGI said it is confident in its own technology, which cost billions of yuan to develop and “broke the market monopoly in the upstream genome sequencing market.”

When interviewed by Caixin earlier this month on whether Illumina will file more suits against BGI outside Europe, the company’s Chief Commercial Officer Mark Van Oene said Illumina will continue pursuing patent protection, without elaborating.

Established in 1999, BGI was a client of Illumina’s sequencing equipment but has started to develop its own devices after purchasing U.S. genomics company Complete Genomics in 2012.

Related: BGI Genomics’ Profits Slip As Questions Linger About Its Services


Share this article
Open WeChat and scan the QR code